Oral EEP - Heart

304 - Disparities in Utilization of Hepatitis C Virus Positive Hearts for Transplantation

Presentation Number
304
Speakers
Session Name
SESSION 74 - ORAL: Frontiers of Cost-Efficacy and Policy in Transplant and MCS
Date
Sat, Apr 06, 2019
Time
10:15 AM - 12:00 PM
Authors (listed alphabetically)

Previous Eposter
219 - Novel Descriptors of Coronary Wall Properties Measured by OCT at Baseline Are Associated with CAV-Related Intimal Thickening One Year after Heart Transplant

Next Eposters
33 - Sequential Measurement of Trypanosoma cruzi Parasitic Load in Endomyocardial Biopsies for Early Detection and Follow-up of Chagas Disease Reactivation After Heart Transplantation
252 - High Afterload Driving Poor Cardiac Output in LVAD Patients is Rectified with Nitrate Therapy
507 - Clinical Utility of the IMPACT Score for Mortality Prediction after Heart Transplantation: External Validation Study
71 - Expanding Benefits from Cardiac Resynchronization Therapy to Exercise-Induced Left Bundle Branch Block in the Setting of Advanced Heart Failure: A Case Report
126 - Proinflammatory Cytokines as Biomarkers for BOS, Death, or Retransplantation after Lung Transplantation
432 - Conditioned Medium from Mesenchymal Stem Cells Protects Vascular Grafts of Brain-Dead Rats against In Vitro Ischemia/Reperfusion Injury
326 - Lung Ultrasound May Reduce Heart Failure Hospitalizations: Preliminary Results from the LUS-HF Trial
548 - Less Delayed Chest Closure, Systemic Edema, and Postoperative Bleeding in Lung Transplantation Using ECMO, Compared with CPB
363 - Alpha1-Antitrypsin Therapy Suppresses Acute Rejection in an Orthotopic Murine Lung Transplantation Model
469 - QOLVAD Detects Changes in Emotional, Social, Cognitive and Physical Wellbeing after Continuous-Flow LVAD Implant